Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder

International Clinical Psychopharmacology

Volumn 27, Issue 4, 2012, Pages 197-207

  Baldwin, David S ^a   Loft, Henrik ^b   Florea, Ioana ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b H LUNDBECK A S   (Denmark)

Author keywords

generalized anxiety disorder; Lu AA21004; multimodal; placebo controlled; randomized clinical trial; relapse prevention

Indexed keywords

PLACEBO; VORTIOXETINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HAZARD RATIO; HEADACHE; HUMAN; INFLUENZA; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SULFIDES;

EID: 84862138398     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283530ad7     Document Type: Article

References (29)

1. Allgulander C, Florea I, Huusom AKT (2006). Prevention of relapse in generalised anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:495-505. (Pubitemid 44607202)
2. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F (2011). A double-blind, randomised, placebo-controlled, active-reference study of Lu AA21004 in patients with major depressive disorder (MDD). Int J Neuropsychopharmacol 18 July 2011. [Epub ahead of print].
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision (DSM-IV-TR) Washington, DC: American Psychiatric Association.
4. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT, et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596. (Pubitemid 41578819)
5. Baldwin DS, Loft H, Dragheim M (2011). A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in MDD treatment. Eur Neuropsychopharmacol 21 (Suppl 3): S390.
6. Baldwin DS, Waldman S, Allgulander C (2011). Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 14:697-710.
7. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, et al. (2011). Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl] piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54:3206-3221.
8. Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV (2011). Efficacy and tolerability of 5 mg Lu AA21004 in an 8-week European trial of adults with generalized anxiety disorder. Neuropsychopharmacology 36:S224-S225.
9. Boulenger J-P, Loft H, Florea I (). Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol (in press).
10. Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, et al. (2008). Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 18:673-681.
11. European Medicines Agency (2005). Committee for Proprietary Medicinal Products (CPMP). Guideline on the clinical investigation of medicinal products indicated for generalised anxiety disorder. CPMP/EWP/4284/02.
12. Goodwin GM, Emsley R, Rembry S, Rouillon F, et al. Agomelatine Study Group (2009). Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 70: 1128-1137.
13. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. Revised ed. Rockville, MD: National Institute of Mental Health.
14. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
15. Henigsberg N, Mahableshwarkar A, Jacobsen P, Chen Y, Thase ME (2011). Efficacy and tolerability of multiple doses of Lu AA21004 in an 8-week trial of adults with major depressive disorder. Eur Neuropsychopharmacol 21 (Suppl 3):S393.
16. ICH (1996). ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice.
17. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H (2011). Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a longterm, randomized, placebo-controlled trial. Int Clin Psychopharmacol 26: 11-24.
18. Laughren T (2005). Food and Drug Administration, Center for Drug Evaluation and Research. Memorandum on long-term efficacy for psychiatric drugs. Available at http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272 b1-01-fda.pdf. [Accessed 20 December 2011].
19. Laughren T (2006). Food and Drug Administration, Center for Drug Evaluation and Research. Memorandum on Suicidality. Available at http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-fda.pdf. [Accessed 20 December 2011].
20. Llorca PM, Bodkin JA, Spann M, Ball SG, Russell JM, Ball SG (2009). A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawal relapse prevention study design. J Clin Psychopharmacol 29:96-97.
21. Montgomery S, A ° sberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
22. Mørk A, Montezinho LC, Hovelsø N, Karlsson JJ, Murphy CT, Plath N, et al. (2011). Lu AA21004, a novel antidepressant, modulates neurotransmitter levels and theta oscillations, and exerts pro-cognitive effects in rats. Eur Neuropsychopharmacol 21 (Suppl 3):S407-S408.
23. Posner K, Oquendo MA, Gould M, Stanley B, Davies M (2007). Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043. (Pubitemid 47121392)
24. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV (2011). Efficacy and tolerability of 5 mg Lu AA21004 in an 8-week US trial of adults with generalized anxiety disorder. Neuropsychopharmacology 36: S225-S226.
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20):22-33. (Pubitemid 29001829)
26. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, et al. (2003). Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250-258. (Pubitemid 36457322)
27. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC (2000). Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 15:319-328.
28. Wittchen HU, Beesdo K, Bittner A, Goodwin RD (2003). Depressive episodes-evidence for a causal role of primary anxiety disorders? Eur Psychiatry 18:384-393. (Pubitemid 38009821)
29. World Medical Association (2002). Declaration of Helsinki: ethical principles for medical research involving human subjects. Available at http://www. wma.net/en/30publications/10policies/b3/17c.pdf. [Accessed 9 March 2012].